Aurobindo Pharma's Unit CuraTeQ Gets UK Nod For Third Biosimilar

Aurobindo Pharma Ltd. on Tuesday said its wholly owned step-down subsidiary CuraTeQ Biologics s.r.o. has received approval from the UK's Medicines and Healthcare products Regulatory Agency to market Dyrupeg, a biosimilar of pegylated filgrastim.

This marks CuraTeQ’s third biosimilar approval in the UK, following nods for Bevqolva in December 2024 and Zefylti in May 2025, the company said in a stock exchange filing.

Dyrupeg was also approved for marketing in the European Union by the European Commission in April.